Shaji Kumar, ASH 2022: Highlights in high-risk newly-diagnosed multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of high-risk newly-diagnosed multiple myeloma, where it is fundamental to risk stratify patients and develop different treatment strategies.
Abstract 752: Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma (00:40-01:40)
Abstract 758: Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial (01:40-02:20)
Abstract 759: Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial (02:20-02:50)
Disclosures: Shaji Kumar discloses research funding for clinical trials to the institution from: Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio and Molecular Templates; Consulting/Advisory Board participation (with no personal payments) from: Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium and (with personal payment) Oncopeptides, Beigene, Antengene and GLH Pharma.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 64th ASH Annual Meeting & Exposition
